<DOC>
	<DOC>NCT00175825</DOC>
	<brief_summary>This trial will evaluate the efficacy and safety of brivaracetam (at doses of 5, 20 and 50 mg/day in twice a day administration) as add-on therapy in subjects with focal epilepsy.</brief_summary>
	<brief_title>A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<criteria>Male/female from 16 to 65 years. Wellcharacterized focal epilepsy or epileptic syndrome according to the International League Against Epilepsy (ILAE) classification. History of partial onset seizures. Subjects having at least 4 partial onset seizures during the 4week Baseline Period and at least 2 partial onset seizures during the 3 months prior to Visit 1. Subjects taking 1 or 2 concomitant Antiepileptic drugs (AED(s)) that have been at a stable dose. Seizure type IA nonmotor as only seizure type. Seizures occurring only in clusters. Status epilepticus during the last 2 years before Visit 1. History of cerebrovascular accident (CVA). Presence of any sign suggesting rapidly progressing brain disorder or brain tumor.</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Epilepsy: partial onset seizures</keyword>
	<keyword>brivaracetam</keyword>
</DOC>